EVM
HRMY icon

Eaton Vance Management’s Harmony Biosciences HRMY Stock Holding History

Eaton Vance Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-366
Closed -$16K – 2211
2021
Q4 		$16K Buy
+366
New +$14.6K ﹤0.01% 2443

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eaton Vance Management's HRMY Position: Q1 2022 in Review

Eaton Vance Management sold out of Harmony Biosciences (HRMY) in Q1 2022, closing a stake of 366 shares — an estimated $16K sold.

Eaton Vance Management first reported a position in HRMY in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 182 funds tracked by Wall St. Rank hold HRMY as of Q1 2022.

  • Eaton Vance Management reported no remaining Harmony Biosciences position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 366 Harmony Biosciences shares in Q1 2022, an estimated $16K.
  • Eaton Vance Management first reported a position in Harmony Biosciences in Q4 2021 and held it in 1 quarter.
  • Eaton Vance Management's Harmony Biosciences position peaked at $16K in Q4 2021.
  • 182 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.